Do GLP-1–Based Therapies Increase Cancer Risk?
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Cases of pancreatitis have been de-scribed in connection with the useof exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 re-ceptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with re-spective agonists has a potential to cause pancreatitis, perhaps chronic pancreati-tis, and in the long term, potentially even pancreatic cancer (3–5). Further-more, in rodents like mice and rats, stim-ulating the GLP-1 receptor raises cAMP in thyroid C cells, initiates the release of cal-citonin, and upon longer-term exposure, is accompanied by C-cell proliferation and the formation of C-cell adenomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is evidence that GLP-1 analogues increase the risk of medullary thyroid cancer, which is a cause for concern.268”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [268]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“For the purpose of this review, GLP-1–based therapies are GLP-1 receptor agonists such as exenatide, liraglutide, and others or dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin (8).”
BackgroundSelf-citationVincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“It takes another 7 years (approximately) for such cells to develop subclones with metastatic capacity and another 3 years (approximately) before the disease will be diagnosed due to clinical symptoms and a clinically apparent primary tumor accompanied by metastases (13).”
BackgroundUnder-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 8×
“(3), we looked at subcategories of malignant disease entities.”
BackgroundMethodInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“C-cell disease ranges from C-cell hyperplasia to C-cell adenoma and medullary carcinoma (6).”
BackgroundInfluentialDeterminants of Under-Reporting of Adverse Drug Reactions: A Systematic Review
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00002 · Cited by 574
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“In mice and rats, a once-daily injection of liraglutide, a GLP-1 receptor agonist that has an approximate half-life of 13 h, leads to permanently elevated circulating drug concentrations (32,33) and increased rate of C-cell abnormalities in both mice and rats, with some animals developing C-cell carcinomas, especially…”
Background
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“When GLP-1 RAs were introduced as novel agents to treat type 2 diabetes, there was uncertainty about several potential adverse effects such as acute pancreatitis, pancreatic cancer, and thyroid cancer [102,103].”
BackgroundSelf-citationBethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Detailed discussions of pancreatitis potentially induced by DPP-4 inhibitors have been published [51,52].”
BackgroundSelf-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Acute pancreatitis may potentially progress to chronic pancreatitis and ultimately develop pancreatic cancer (Yachida et al., 2010; Nauck and Friedrich, 2013).”
BackgroundMethodBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Self-citationReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
“Thyroid Safety and Calcitonin Levels In rodent models, GLP-1RAs have been linked to the release of calcitonin, and the potential formation of thyroid tumours [79], but there is no evidence of a causal relationship between GLP-1RAs and thyroid tumours in humans.”
BackgroundDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Self-citationSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“Early concerns about increased pancreatitis [177, 178] and medullary thyroid cancer risk [177, 179] with GLP-1 receptor agonists have not been substantiated in the large outcome studies [25–27, 115], nor in recent meta-analyses of RCTs [180, 181].”
BackgroundOptical control of insulin release using a photoswitchable sulfonylurea
Broichhagen, J., Schönberger, M., Cork, S. C., Frank, J. A., Marchetti, P., Bugliani, M., Shapiro, A. M. J., Trapp, S., Rutter, G. A., Hodson, D. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6116 · Cited by 145
“However, debate still exists as to whether incretin-based therapies are associated with increased risk of pancreatitis and pancreatic adenocarcinoma 48,49 .”
Kalra, S., Aggarwal, S., & Khandelwal, D. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00700-4 · Cited by 128
Aras, M., Tchang, B. G., & Pape, J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.008 · Cited by 108
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Due to the promotive effect of GLP-1R agonism on b-cells proliferation and survival, concerns of tumorigenesis, especially pancreatic cancers, have been raised about incretinbased therapies (89).”
BackgroundGlucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Exenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 105
“0; p-value not reported), although this is based on spontaneous adverse event (AE) reports and therefore may be affected by reporting bias [44].”
BackgroundBurden of cancer attributable to obesity, type 2 diabetes and associated risk factors
López-Suárez, A. (2018) · Metabolism · doi:10.1016/j.metabol.2018.10.013 · Cited by 115
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Aleman, J. O., Weintraub, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 93
“Despite previous concerns regarding pancreatitis and medullary thyroid cancer risk associated with GLP-1 RA use (67), this was not substantiated in LEADER, SUSTAIN-6, nor in a recent meta-analysis of all four CV outcome trials combined (68).”
Management of diabesity: Current concepts
Michaelidou, M., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.396 · Cited by 145
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Chronomedicine and type 2 diabetes: shining some light on melatonin
Forrestel, A. C., Miedlich, S. U., Yurcheshen, M. E., Wittlin, S. D., & Sellix, M. T. (2016) · Diabetologia · doi:10.1007/s00125-016-4175-1 · Cited by 87
Melatonin, mitochondria, and the metabolic syndrome
Cardinali, D. P., & Vigo, D. E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2611-0 · Cited by 80
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“Pancreatitis, medullary thyroid cancer, and gallbladder-related disorders are serious side effects that may appear only after chronic use in larger groups of individuals [80,85].”
BackgroundEfficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
“Cases of pancreatitis have been described in connection with the use of GLP-1RAs, including exenatide and liraglutide, and also with DPP-4 inhibitors such as sitagliptin [54,55].”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 195
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 76
“Whether GLP-1 analogs increase the risk for pancreatic or thyroid cancer remains unknown as well, but animal models suggest at least a theoretical risk although no conclusive evidence in humans is available.(19) This class of medications is a viable option for patients intolerant to metformin.”
BackgroundFiglioli, G., Piovani, D., Peppas, S., Pugliese, N., Hassan, C., Repici, A., Lleò, A., Aghemo, A., & Bonovas, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107401 · Cited by 68
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“Although findings of this type of studies are marred by several bias (un-adjudicated diagnoses and incidence rate for the outcomes of interest likely overestimated), these studies concur in supporting the notion that current available evidence is insufficient to support an increased risk of acute pancreatitis or an in…”
ResultPandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
Zhou, M., Mok, M. T. S., Sun, H., Chan, A. W. H., Huang, Y., Cheng, A. S. L., & Xu, G. (2017) · Oncogene · doi:10.1038/onc.2017.38 · Cited by 63
Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs
Arora, A., Jalali, R., & Vohora, D. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s137144 · Cited by 64
“The detection bias arises as the number of reported AEs rise because of the tests that are performed to confirm or rule out a suspected AE.”
InfluentialPathophysiology after pancreaticoduodenectomy
Kang, C. M., & Lee, J. H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5794 · Cited by 62
New-Onset Diabetes after Kidney Transplantation
Ponticelli, C. E., Favi, E., & Ferraresso, M. (2021) · Medicina · doi:10.3390/medicina57030250 · Cited by 62
“However, the evidence in favor of the hypothesis that GLP-1 inhibitors cause specific types of malignant disease or increase the risk for cancer is not convincing enough [81].”
BackgroundIrwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 59
Obesity and multiple myeloma: Emerging mechanisms and perspectives
Tentolouris, A., Ntanasis‐Stathopoulos, I., & Terpos, E. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.003 · Cited by 62
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s164785 · Cited by 54
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12541 · Cited by 56
“The incidence rates of pancreatitis, pancreatic cancer and thyroid cancer were also assessed because of previously reported concerns that incretin-based therapies might increase the risk of these malignancies [12] or pancreatitis [13].”
BackgroundSharma, N., Soni, R., Sharma, M., Chatterjee, S., Parihar, N., Mukarram, M., kale, R., Sayyed, A. A., Behera, S. K., & Khairnar, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03005-z · Cited by 55
Spinedi, E., & Cardinali, D. P. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1349868 · Cited by 52
“Drug therapies are expensive worldwide and in some cases have been associated with adverse secondary events including pancreatitis, hypoglycemia, and osteoporosis [102, 103].”
BackgroundAnti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 52
“Concerns also extend to the association between GLP-1 RAs and pancreatic cancer, as chronic pancreatitis, a potential side effect of GLP-1 RAs, is linked to an increased risk of malignancy [102].”
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“The studies on cancer risk associated with incretin-based therapies by using the FDA adverse events reporting system have also been criticized for a lack of appropriate adjustment for confounders, channeling bias, disproportionate reporting, Weber effect, and detection bias [109, 176].”
BackgroundLiraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
Mali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
Inzucchi, S. E. (2017) · Diabetes Care · doi:10.2337/dc16-2372 · Cited by 50
“genesis appear to be diminishing (31), but additional long-term safety data are still needed.”
BackgroundJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“These searches have been reproduced with almost identical results (66), leading to the definition of acute pancreatitis as an “adverse event of special interest” in clinical trials of GLP-1RAs.”
Self-citationIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0370-5 · Cited by 39
Rathmann, W., & Kostev, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.012 · Cited by 36
“So far, results from randomized controlled trials whether DPP-4i may promote specific types of cancer or may increase cancer risk in general are inconclusive (Nauck & Friedrich, 2013).”
BackgroundSasaki, S., Miyatsuka, T., Matsuoka, T., Takahara, M., Yamamoto, Y., Yasuda, T., Kaneto, H., Fujitani, Y., German, M. S., Akiyama, H., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3728-z · Cited by 36
Zhao, Y., Wang, Y., Lou, H.-Y., & Shan, L. (2017) · Oncotarget · doi:10.18632/oncotarget.17515 · Cited by 36
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
“myeloma, metastasizing tumors of unknown origin, and other tumors not specified.(54) The potential role of incretin therapies in pancreatic adverse effects requires prospective trials that are appropriately designed and powered to assess this question.”
BackgroundLiu, Y., Jiang, X., & Chen, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0609-0 · Cited by 31
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“5 and Table 5) Many worry that incretin-based therapy could lead to carcinogenesis, particularly pancreatic tumors, because of the stimulatory effects of GLP-1RA on β -cell proliferation and survival [137].”
Obesity and cancer: at the crossroads of cellular metabolism and proliferation
O’Rourke, R. W. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.08.012 · Cited by 35
Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Development of peptide therapeutics: A nonclinical safety assessment perspective
Mitra, M. S., DeMarco, S. J., Holub, B., Thiruneelakantapillai, L., & Thackaberry, E. A. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104766 · Cited by 27
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Ng, E., Shaw, J. E., Wood, A. J., Maple-Brown, L. J., & Hare, M. J. L. (2022) · Australian Journal of General Practice · doi:10.31128/ajgp-07-21-6057 · Cited by 30
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., & Mitro, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.005 · Cited by 32
Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
Chis, B. A., & Fodor, D. (2018) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-804 · Cited by 26
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
Papanagnou, P., Stivarou, T., & Tsironi, M. (2016) · Pharmaceuticals · doi:10.3390/ph9020024 · Cited by 26
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz137 · Cited by 27
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., et al. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s305496 · Cited by 24
“Rates of spontaneous reports of TC from 2004 through 2009 were elevated with exenatide, another GLP-1 RA.(8,9) Although spontaneous reporting systems enable identification of a range of potential safety signals, biased reporting is common and often profound; therefore, evidence on GLP-1 RA and TC has been sparse and i…”
BackgroundMethodResultInfluentialSphingosine Kinase 1 Isoform-Specific Interactions in Breast Cancer
Yagoub, D., Wilkins, M. R., Lay, A. J., Kaczorowski, D. C., Hatoum, D., Bajan, S., Hutvágner, G., Lai, J. H.-S., Wu, W., Martiniello‐Wilks, R., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1423 · Cited by 25
Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Martins, E. B., Lima, E. G., Pitta, F. G., Carvalho, L. N. S., de Queiroz, T. D., & Junior, C. V. S. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.9.1283 · Cited by 25
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022) · Biomolecules · doi:10.3390/biom12111580 · Cited by 24
C-cells and their associated lesions and conditions: a pathologists perspective
Baloch, Z. W., & LiVolsi, V. A. (2015) · Turkish Journal of Pathology · doi:10.5146/tjpath.2015.01315 · Cited by 28
Kuo, C.-C., Chuang, M., Li, C., Tsai, Y., Huang, P., Kuo, H., & Lai, C.-C. (2025) · Diabetologia · doi:10.1007/s00125-025-06453-z · Cited by 22
“Common side effects of GLP-1RAs include nausea, vomiting, diarrhoea and constipation, while more serious adverse effects, such as pancreatitis, bowel obstruction, gastroparesis and biliary tract diseases, have also been reported [8–10].”
Adverse Effects Associated With Newer Diabetes Therapies: A Review Article
Akiyode, O., & Adesoye, A. A. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015594732 · Cited by 23
The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy
Parmar, C. D., Mosleh, K. A., Aeschbacher, P., Halfdanarson, T. R., McKenzie, T. J., Rosenthal, R. J., Ghanem, O. M., Heneghan, H., Brennan, D. J., Wilkinson, M., et al. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.02.008 · Cited by 21
Nauck, M. A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154031 · Cited by 22
Self-citationLi, C., Kuang, J., Zhao, Y., Sun, H., & Guan, H. (2020) · Endocrine · doi:10.1007/s12020-020-02291-8 · Cited by 21
Germano, J. D. F., Huang, C., Sin, J., Song, Y., Tucker, K. C., Taylor, D. J. R., Saadaeijahromi, H., Stotland, A. B., Piplani, H., Gottlieb, R. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64924-2 · Cited by 21
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Heimbürger, S. M. N., Brønden, A., Johansen, N. J., Dejgaard, T. F., Vilsbøll, T., & Knop, F. K. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571040 · Cited by 20
Zhong, Y., Wu, T., & Khan, N. U. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04211-4 · Cited by 19
“Some studies have also raised concerns about their potential to increase the risk of gastrointestinal and colorectal cancers [9, 10].”
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 20
Owolabi, B. O., Ojo, O. O., Srinivasan, D. K., Conlon, J. M., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1243-5 · Cited by 18
Frías, J. P., DEX, T. A., Roberts, M., & Kaplan, A. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0547-5 · Cited by 18
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“An analysis of data reported to the FDA adverse event reporting system did seem to show an increased risk of pancreatic and thyroid cancer with incretin therapies, although the data were not consistent and have been discredited on the basis of a bias in reporting of events [77,78].”
MethodWhat is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
“…mg, or tirzepatide and other types of cancer was evident in the clinical development programs involving PLWO [1 – 16], concern has been raised on the potential association between the chronic use of this family of drugs and the incidence of cancer, especially of thyroid or pancreatic origin [60].”
Niu, C., Sun, K., Zhang, J., Elkhapery, A. M. R., Zhu, K., Malik, S., Xue, C., & Okolo, P. I., III (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003760 · Cited by 18
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19
“The basis for the black box warning is derived primarily from animal experiments; in rodent experi‐ ments, there is evidence of a greater incidence of thyroid C-cell tumours in response to the use of GLP-1 RAs (such as liraglutide, exenatide, and lixisenatide) [27, 28].”
Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
Clapham, J. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9882-1_1 · Cited by 19
Weight Recidivism After Bariatric Surgery: A Narrative Review
Cao, Q., Kazi, H., Merchant, A. M., & Jawed, A. E. (2025) · The American Surgeon · doi:10.1177/00031348251337161 · Cited by 14
“73 Hy-poglycemia is generally uncommon but can occur when these medications are used in combination with insulin or sulfonylureas.”
New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 14
“Reassuringly, after review of currently available data, the US food and Drug Administration and the European Medicines Agency have agreed that there is insufficient evidence to confirm an increased risk of cancer and pancreatitis with the use of GLP-1 receptor analogues, however GLP-1 receptor analogues should be cont…”
BackgroundDiabetes mellitus and multiple myeloma; common features of two distinct entities
Tentolouris, A., Ntanasis‐Stathopoulos, I., Eleftheriadou, I., Malandrakis, P., Tzeravini, E., & Gavriatopoulou, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3535 · Cited by 16
Wang, M.-W., & Lu, L. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00271 · Cited by 17
“164 Notably, larger doses or longer durations of GLP-1RA therapy have been associated with an increased risk of cholelithiasis, 165 a primary risk factor for AP.”
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13
“Yet, the same GLP-1 receptor agonists, and recently a DPP4 inhibitor (alogliptin), were shown to be associated with a drug-related c-cell thyroid neoplasia signal in rodents (presumably through the GLP-1 receptor on thyroid ccells) [75,76] supporting the validity of rodent carcinogenicity studies in identifying long a…”
BackgroundSherman, S. I., Kloos, R. T., Tuttle, R. M., Pontecorvi, A., Völzke, H., Harper, K. D., Vance, C., Alston, J. T., Usborne, A. L., Sloop, K. W., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13437 · Cited by 15
Drzazga, A. K., Kamińska, D., Gliszczyńska, A., & Gendaszewska‐Darmach, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115748 · Cited by 13
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 12
Pancreatic Safety of Newer Incretin-Based Therapies: Are the “-tides” Finally Turning?
Devaraj, S., & Maitra, A. (2014) · Diabetes · doi:10.2337/db14-0545 · Cited by 12
Grossman, S. S. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0101-4 · Cited by 11
“A subsequent analysis of the same database found that whereas spontaneous reports of pancreatic cancer were indeed higher, reports of several other cancers were significantly lower in incretin users [55].”
GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus
Dahiya, L., Kaur, R., Kumar, R., Kumar, M., & Palta, K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190502114924 · Cited by 16
Metadata
- Authors
- Nauck, M. A., & Friedrich, N.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Universität Greifswald (DE)
- Corresponding author
- Friedrich, Nele
- ORCID
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S245-S252
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3920789
- OpenAlex
- W2158762809
- Cited by
- 145
- References
- 56
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 17 · 2016: 12 · 2015: 13 · 2014: 17 · 2013: 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, exenatide, liraglutide, pancreatitis, chronic pancreatitis, pancreatic cancer, thyroid C cells, calcitonin, cAMP signaling, cancer risk
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, Risk Factors, Thyroid Neoplasms, Glucagon-Like Peptide 1, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.